Evidence map›Paper›PMID 31212961›Full record

ArticleToxins2019

Recombinant Antibodies against Mycolactone.

Leslie Naranjo, Fortunato Ferrara, Nicolas Blanchard, Caroline Demangel, Sara D'Angelo, M Frank Erasmus, Andre A Teixera, Andrew R M Bradbury

Open access · goldAbstract read
In one paragraph

Article in Toxins, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Buruli ulcer.Nature reviews. Disease primers · 2025
    Review
  2. Article
  3. Review
  4. The Many Hosts of Mycobacteria 8 (MHM8): A conference report.Tuberculosis (Edinburgh, Scotland) · 2020
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Leslie NaranjoSpecifica Inc., Santa Fe, NM 87505, USA. lnaranjo@specifica.bio.
Fortunato FerraraSpecifica Inc., Santa Fe, NM 87505, USA. fferrara@specifica.bio.
Nicolas BlanchardUniversité de Haute-Alsace, Université de Strasbourg, CNRS, LIMA, UMR 7042, 68000 Mulhouse, France. n.blanchard@unistra.fr.ORCID 0000-0002-3097-0548
Caroline DemangelImmunobiology of Infection Unit, Institut Pasteur, INSERM U1221, 75015 Paris, France. caroline.demangel@pasteur.fr.ORCID 0000-0001-7848-586X
Sara D'AngeloSpecifica Inc., Santa Fe, NM 87505, USA. sdangelo@specifica.bio.
M Frank ErasmusSpecifica Inc., Santa Fe, NM 87505, USA. ferasmus@specifica.bio.
Andre A TeixeraSpecifica Inc., Santa Fe, NM 87505, USA. ateixeira@specifica.bio.
Andrew R M BradburySpecifica Inc., Santa Fe, NM 87505, USA. abradbury@specifica.bio.
Specifica (United States) · USCentre National de la Recherche Scientifique · FRInserm · FRNew Mexico Consortium · US

Funding

Closing the Gaps on Buruli Ulcer Diagnosis, Treatment, and PreventionR01AI113266 · NIAID · JOHNS HOPKINS UNIVERSITY · PI NUERMBERGER, ERIC L · 2016 to 2020
$4.4M
NIAID NIH HHS R01 AI113266
6 · The paper itself

Abstract

In the past, it has proved challenging to generate antibodies against mycolactone, the primary lipidic toxin A of

Indexed as

Antibodies, MonoclonalBiotinylationHigh-Throughput Nucleotide SequencingHumansMacrolidesRecombinant ProteinsYeastsAntibodies, MonoclonalMacrolidesmycolactoneRecombinant ProteinsBuruli ulcermycolactonephage displayrecombinant antibodysingle chain Fvyeast display

Identifiers

PMID31212961
PMCPMC6628451
OpenAlexW2953022741

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.